Global law firm Baker McKenzie has advised McKesson Corporation on its agreement to acquire Precision Medicine Group, LLC in a transaction valued at approximately USD 2.25 billion. The acquisition marks another significant milestone in the healthcare and life sciences sector, strengthening McKesson’s position within clinical research and biopharmaceutical commercialisation services.

The transaction highlights the growing importance of precision medicine and reinforces the increasing demand for specialist legal expertise in complex, cross-border mergers and acquisitions.

Experienced Legal Team Delivers Cross-Border Expertise

The Baker McKenzie team was led by M&A Partner Darcy Down, supported by a multidisciplinary group of lawyers covering corporate transactions, intellectual property, data protection, regulatory matters, employment, executive compensation and real estate. Lawyers from across the firm’s international network also contributed to the successful execution of the deal.

By bringing together specialists from multiple practice areas, Baker McKenzie demonstrated its ability to manage sophisticated transactions that require both commercial insight and deep regulatory knowledge.

Strengthening the Future of Healthcare Innovation

McKesson’s acquisition of Precision Medicine Group reflects the continued evolution of personalised healthcare and the increasing investment in clinical research and biopharmaceutical services. As healthcare providers and life sciences organisations continue to innovate, transactions of this scale are becoming increasingly important in accelerating medical research, improving patient outcomes and expanding access to advanced therapies.

With extensive experience advising organisations operating within highly regulated industries, Baker McKenzie remains a trusted legal adviser for companies pursuing transformational growth opportunities.

A Global Law Firm with a Proven Track Record

For more than 75 years, Baker McKenzie has helped businesses navigate changing markets, regulatory developments and international expansion. Today, the firm boasts more than 2,500 deal practitioners across over 40 countries, making it one of the world’s leading advisers on cross-border transactions.

Its Healthcare & Life Sciences practice is recognised for combining international reach with local expertise, enabling clients to complete high-value transactions with confidence. The McKesson acquisition of Precision Medicine Group further reinforces Baker McKenzie’s reputation for delivering strategic legal advice on some of the world’s most significant corporate deals.

Media Contact

For further information regarding Baker McKenzie’s role in the McKesson acquisition or to arrange media enquiries, please contact:

Patricia Lojo
Associate Director, Media Relations – North America
Tel: + 1 212 626 4363
Email: patricia.lojo@bakermckenzie.com